135 related articles for article (PubMed ID: 10963376)
21. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery.
Bode-Lesniewska B; Zhao J; Speel EJ; Biraima AM; Turina M; Komminoth P; Heitz PU
Virchows Arch; 2001 Jan; 438(1):57-65. PubMed ID: 11213836
[TBL] [Abstract][Full Text] [Related]
22. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
[TBL] [Abstract][Full Text] [Related]
23. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
24. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
[TBL] [Abstract][Full Text] [Related]
25. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma.
Sugimachi K; Aishima S; Taguchi K; Tanaka S; Shimada M; Kajiyama K; Sugimachi K; Tsuneyoshi M
J Hepatol; 2001 Jul; 35(1):74-9. PubMed ID: 11495045
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
28. Elevated expression of G
Cao XY; Ji HJ; Zhou YJ; Lu XF; Shen JY; Wu ZR; Bu H; Shi YJ
Hepatobiliary Pancreat Dis Int; 2017 Dec; 16(6):638-644. PubMed ID: 29291784
[TBL] [Abstract][Full Text] [Related]
29. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma.
Kang YK; Kim WH; Lee HW; Lee HK; Kim YI
Lab Invest; 1999 Apr; 79(4):477-83. PubMed ID: 10212000
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical status of p53, mdm2 and Ki-67 in malignant fibrous histiocytoma.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1998; 49(1):15-21. PubMed ID: 9640970
[TBL] [Abstract][Full Text] [Related]
31. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
32. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
[TBL] [Abstract][Full Text] [Related]
33. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.
Sarcognato S; Gringeri E; Fassan M; Di Giunta M; Maffeis V; Guzzardo V; Cillo U; Guido M
Virchows Arch; 2019 Jan; 474(1):29-37. PubMed ID: 30377796
[TBL] [Abstract][Full Text] [Related]
34. [The expression of Mdm2 protein and p53 mutation in lung squamous cell carcinomas and their clinicopathological significance].
Zhang J; Liu H; Li S; Gu C
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar; 22(3):163-5. PubMed ID: 11812371
[TBL] [Abstract][Full Text] [Related]
35. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.
Li J; Tian F; Li D; Chen J; Jiang P; Zheng S; Li X; Wang S
FEBS Lett; 2014 Sep; 588(18):3491-500. PubMed ID: 25131931
[TBL] [Abstract][Full Text] [Related]
36. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
[TBL] [Abstract][Full Text] [Related]
37. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
38. [Genotyping of multiple genetic alterations of intrahepatic cholangiocarcinoma].
Cong W; Wu M; Chen H
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):271-3. PubMed ID: 11798885
[TBL] [Abstract][Full Text] [Related]
39. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue.
Stefanaki K; Tzardi M; Kouvidou C; Chaniotis V; Bolioti M; Vlychou M; Zois M; Kakolyris S; Delides G; Rontogianni D; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(4A):2403-8. PubMed ID: 9703886
[TBL] [Abstract][Full Text] [Related]
40. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
